Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes

Dipeptidyl peptidase-4 (DPP-4) is a well-known therapeutic drug target proven to reduce blood glucose levels in diabetes mellitus, and clinically, DPP-4 inhibitors are used in combination with other anti-diabetic agents. However, side effects and skeletal muscle health are not considered in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalhotra, Poonam, Chittepu, Veera C. S. R., Osorio-Revilla, Guillermo, Gallardo-Velázquez, Tzayhri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429117/
https://www.ncbi.nlm.nih.gov/pubmed/30862104
http://dx.doi.org/10.3390/ijms20051228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429117/
https://www.ncbi.nlm.nih.gov/pubmed/30862104
http://dx.doi.org/10.3390/ijms20051228

Ejemplares similares